Reduced haloperidol (BioDeep_00000018252)
human metabolite Endogenous blood metabolite
代谢物信息卡片
4-(4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol
化学式: C21H25ClFNO2 (377.1557752)
中文名称:
谱图信息:
最多检出来源 Mus musculus(blood) 44.44%
分子结构信息
SMILES: C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(C3=CC=C(C=C3)F)O
InChI: InChI=1S/C21H25ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,20,25-26H,1-2,11-15H2
描述信息
Reduced haloperidol is a metabolite of haloperidol. Haloperidol is a typical antipsychotic. It is in the butyrophenone class of antipsychotic medications and has pharmacological effects similar to the phenothiazines. Haloperidol is an older antipsychotic used in the treatment of schizophrenia and acute psychotic states and delirium. (Wikipedia)
同义名列表
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:177583
- PubChem: 119265
- HMDB: HMDB0060903
- ChEMBL: CHEMBL1036
- CAS: 34104-67-1
- PMhub: MS000004614
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
1 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Naoya Kishikawa, Chiyuki Hamachi, Yoshihiro Imamura, Yoshihito Ohba, Kenichiro Nakashima, Yashuhiro Tagawa, Naotaka Kuroda. Determination of haloperidol and reduced haloperidol in human serum by liquid chromatography after fluorescence labeling based on the Suzuki coupling reaction.
Analytical and bioanalytical chemistry.
2006 Oct; 386(3):719-24. doi:
10.1007/s00216-006-0755-0. [PMID: 16957915] - Akihito Suzuki, Norio Yasui-Furukori, Kazuo Mihara, Tsuyoshi Kondo, Hanako Furukori, Yoshimasa Inoue, Sunao Kaneko, Koichi Otani. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
Therapeutic drug monitoring.
2003 Apr; 25(2):192-6. doi:
10.1097/00007691-200304000-00008. [PMID: 12657913] - Tetsuya Arinobu, Hideki Hattori, Hiroshi Seno, Akira Ishii, Osamu Suzuki. Comparison of SSI with APCI as an interface of HPLC-mass spectrometry for analysis of a drug and its metabolites.
Journal of the American Society for Mass Spectrometry.
2002 Mar; 13(3):204-8. doi:
10.1016/s1044-0305(01)00359-2. [PMID: 11908800] - K Mihara, A Suzuki, T Kondo, N Yasui, H Furukori, U Nagashima, S Ono, S Kaneko, K Otani, Y Inoue. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
Therapeutic drug monitoring.
2000 Jun; 22(3):245-9. doi:
10.1097/00007691-200006000-00002. [PMID: 10850389] - L Pan, R Vander Stichele, M T Rosseel, J A Berlo, N De Schepper, F M Belpaire. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.
Therapeutic drug monitoring.
1999 Oct; 21(5):489-97. doi:
10.1097/00007691-199910000-00001. [PMID: 10519444] - S Ulrich, S Neuhof, V Braun, F P Meyer. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
International clinical psychopharmacology.
1999 Jul; 14(4):219-28. doi:
10.1097/00004850-199907000-00003. [PMID: 10468314] - M S Lee, C S Han, Y W You, S H Kim. Co-administration of sertraline and haloperidol.
Psychiatry and clinical neurosciences.
1998 Dec; 52 Suppl(?):S193-8. doi:
10.1111/j.1440-1819.1998.tb03220.x. [PMID: 9895145] - D W Eyles, J J McGrath, T J Stedman, S M Pond. Chirality of reduced haloperidol in humans.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.
1998 May; 8(2):127-9. doi:
10.1016/s0924-977x(97)00049-7. [PMID: 9619691] - H Y Lane, W H Chang, Y C Chang, O Y Hu, H N Lin, M W Jann, W H Hu. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
Psychiatry research.
1997 Sep; 72(2):127-32. doi:
10.1016/s0165-1781(97)00078-4. [PMID: 9335203] - H Hoja, P Marquet, B Verneuil, H Lotfi, J L Dupuy, B Pénicaut, G Lachâtre. Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography-mass spectrometry with electrospray ionization.
Journal of chromatography. B, Biomedical sciences and applications.
1997 Jan; 688(2):275-80. doi:
10.1016/s0378-4347(96)00294-0. [PMID: 9061465] - M W Jann, B L Crabtree, W M Pitts, Y W Lam, J G Carter. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
Neuropsychobiology.
1997; 36(1):32-6. doi:
10.1159/000119357. [PMID: 9211442] - W H Chang, M W Jann, T S Chiang, H N Lin, W H Hu, C P Chien. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
Neuropsychobiology.
1996; 33(1):12-6. doi:
10.1159/000119242. [PMID: 8821369] - D Dutoit, P Thomas, J M Leroux, G Vaiga, J Pommery, O Cottencin, F Erb, M Goudemand. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
L'Encephale.
1995 Nov; 21(6):417-24. doi:
NULL. [PMID: 8674466] - S Ulrich, F P Meyer, S Neuhof, W Knorr. Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: results of therapeutic drug-monitoring during acute therapy of eight schizophrenics.
Journal of chromatography. B, Biomedical applications.
1995 Jan; 663(2):289-96. doi:
10.1016/0378-4347(94)00463-f. [PMID: 7735476] - D W Eyles, T J Stedman, S M Pond. Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms.
Psychopharmacology.
1994 Oct; 116(2):161-6. doi:
10.1007/bf02245058. [PMID: 7862945] - M Aravagiri, S R Marder, T Van Putten, B D Marshall. Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol.
Journal of chromatography. B, Biomedical applications.
1994 Jun; 656(2):373-81. doi:
10.1016/0378-4347(94)00134-0. [PMID: 7987490] - W H Chang, Y S Shieh, H C Liu, M W Jann, C P Chien. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.
1994 Jun; 4(2):119-26. doi:
10.1016/0924-977x(94)90005-1. [PMID: 7919941] - C J Van der Schyf, K Castagnoli, E Usuki, H G Fouda, J M Rimoldi, N Castagnoli. Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice.
Chemical research in toxicology.
1994 May; 7(3):281-5. doi:
10.1021/tx00039a002. [PMID: 8075357] - J M Leroux, E Elia, M Jacquet, J Pommery, J C Levron, P Bouhours, F Erb, D Sechter. Correlation of clinical response (PANSS) and plasma levels of haloperidol and reduced haloperidol in schizophrenia.
Progress in neuro-psychopharmacology & biological psychiatry.
1994 Mar; 18(2):347-53. doi:
10.1016/0278-5846(94)90066-3. [PMID: 8208983] - W H Chang, S K Lin, D J Juang, L C Chen, C H Yang, W H Hu, C P Chien, Y W Lam, M W Jann. Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal.
Schizophrenia research.
1993 Mar; 9(1):35-40. doi:
10.1016/0920-9964(93)90007-6. [PMID: 8461270] - M Shibasaki, T Someya, S Takahashi. Relation of plasma and red blood cells reduced haloperidol concentrations to haloperidol reductase activity assayed in red blood cells in psychiatric population.
Progress in neuro-psychopharmacology & biological psychiatry.
1993 Mar; 17(2):257-67. doi:
10.1016/0278-5846(93)90046-u. [PMID: 8430218] - W H Chang, S K Lin, D J Juang, L C Chen, C H Yang, W H Hu, C P Chien, Y F Lam, M W Jann. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
Progress in neuro-psychopharmacology & biological psychiatry.
1993 Jan; 17(1):105-12. doi:
NULL. [PMID: 8416597] - A Stevens, I Stevens, A Mahal, H J Gaertner. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis.
Pharmacopsychiatry.
1992 Nov; 25(6):273-7. doi:
10.1055/s-2007-1014421. [PMID: 1494594] - T Uematsu, H Matsuno, H Sato, H Hirayama, K Hasegawa, M Nakashima. Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair.
Journal of pharmaceutical sciences.
1992 Oct; 81(10):1008-11. doi:
10.1002/jps.2600811010. [PMID: 1432610] - A Stevens, A Mahal, H J Gaertner. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia.
Pharmacopsychiatry.
1992 Sep; 25(5):218-23. doi:
10.1055/s-2007-1014409. [PMID: 1409866] - A Llerena, M L Dahl, B Ekqvist, L Bertilsson. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.
Therapeutic drug monitoring.
1992 Jun; 14(3):261-4. doi:
10.1097/00007691-199206000-00014. [PMID: 1412613] - M W Dysken, S B Johnson, L Holden, M Kuskowski, J Ofstehage, S Skare, G Vatassery. Haloperidol and reduced haloperidol in saliva and blood.
Journal of clinical psychopharmacology.
1992 Jun; 12(3):186-90. doi:
NULL. [PMID: 1629385] - T Someya, M Shibasaki, T Noguchi, S Takahashi, T Inaba. Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction.
Journal of clinical psychopharmacology.
1992 Jun; 12(3):169-74. doi:
NULL. [PMID: 1629382] - M W Dysken, S W Kim, G Vatassery, S B Johnson, S Skare, L Holden, L Thomsyck. Haloperidol decanoate pharmacokinetics in red blood cells and plasma.
Journal of clinical psychopharmacology.
1992 Apr; 12(2):128-32. doi:
NULL. [PMID: 1573034] - T B Cooper, J Volavka, P Czobor. Plasma drug level and clinical response.
Journal of clinical psychopharmacology.
1992 Apr; 12(2):134-6. doi:
10.1097/00004714-199204000-00011. [PMID: 1573036] - M W Jann, W H Chang, Y W Lam, H G Hwu, H N Lin, H Chen, T Y Chen, S K Lin, C P Chien, C M Davis. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations.
Progress in neuro-psychopharmacology & biological psychiatry.
1992 Mar; 16(2):193-202. doi:
10.1016/0278-5846(92)90070-u. [PMID: 1579637] - W H Chang. Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?.
Psychopharmacology.
1992; 106(3):289-96. doi:
10.1007/bf02245407. [PMID: 1570373] - W H Chang, Y W Lam, M W Jann, H Chen. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.
Psychopharmacology.
1992; 106(4):517-22. doi:
10.1007/bf02244824. [PMID: 1579624] - W H Chang, S K Lin, M W Jann. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
Journal of clinical psychopharmacology.
1991 Apr; 11(2):99-105. doi:
NULL. [PMID: 2056148] - C Cahard, P P Rop, T Conquy, A Viala. High-performance liquid chromatographic analysis of haloperidol and hydroxyhaloperidol in plasma after solid-phase extraction.
Journal of chromatography.
1990 Oct; 532(1):193-202. doi:
10.1016/s0378-4347(00)83769-x. [PMID: 2079535] - R L DesJarlais, G L Seibel, I D Kuntz, P S Furth, J C Alvarez, P R Ortiz de Montellano, D L DeCamp, L M Babé, C S Craik. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease.
Proceedings of the National Academy of Sciences of the United States of America.
1990 Sep; 87(17):6644-8. doi:
10.1073/pnas.87.17.6644. [PMID: 2204060] - T Someya, S Takahashi, M Shibasaki, T Inaba, S W Cheung, S W Tang. Reduced haloperidol/haloperidol ratios in plasma: polymorphism in Japanese psychiatric patients.
Psychiatry research.
1990 Feb; 31(2):111-20. doi:
10.1016/0165-1781(90)90114-k. [PMID: 2326392] - T Someya, M Shibasaki, S Takahashi. [The plasma levels of haloperidol and reduced haloperidol in Japanese psychiatric patients].
Yakubutsu, seishin, kodo = Japanese journal of psychopharmacology.
1989 Jun; 9(2):207-15. doi:
NULL. [PMID: 2816093] - W H Chang, T Y Chen, C F Lee, W H Hu, E K Yeh. Low plasma reduced haloperidol/haloperidol ratios in Chinese patients.
Biological psychiatry.
1987 Nov; 22(11):1406-8. doi:
10.1016/0006-3223(87)90074-6. [PMID: 3663790]